EBIM
IART icon

Eagle Boston Investment Management’s Integra LifeSciences IART Stock Holding History

Eagle Boston Investment Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,477
Closed -$223K – 132
2018
Q2 		$223K Buy
+3,477
New +$215K 0.02% 148
2015
Q2 		– Sell
-27,912
Closed -$703K – 140
2015
Q1 		$703K Buy
+27,912
New +$660K 0.06% 137

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Eagle Boston Investment Management's IART Position: Q3 2018 in Review

Eagle Boston Investment Management sold out of Integra LifeSciences (IART) in Q3 2018, closing a stake of 3,477 shares — an estimated $223K sold.

Eagle Boston Investment Management first reported a position in IART in Q1 2015 and held it in 2 quarters. The position peaked at $703K in Q1 2015. 249 funds tracked by Wall St. Rank hold IART as of Q3 2018.

  • Eagle Boston Investment Management reported no remaining Integra LifeSciences position as of Q3 2018 after selling out during the quarter.
  • Eagle Boston Investment Management sold 3,477 Integra LifeSciences shares in Q3 2018, an estimated $223K.
  • Eagle Boston Investment Management first reported a position in Integra LifeSciences in Q1 2015 and held it in 2 quarters.
  • Eagle Boston Investment Management's Integra LifeSciences position peaked at $703K in Q1 2015.
  • 249 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2018.

Based on Eagle Boston Investment Management's 13F filing for Q3 2018, filed 8 Nov 2018.